Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Regulatoryapprovediohexol injectionPositive

AI Analysis

Summary

Amneal Pharmaceuticals received FDA approval for additional strengths and vial presentations of iohexol injection, expanding its portfolio. The company plans to launch these products in Q3 2026.

Outcome Details

FDA approval for additional strengths and presentations of iohexol injection: 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials; 300 mg iodine/mL in 50 mL vial

Importance:5/10

Sentiment:

0.60

FDA approvalproduct expansioniohexolcontrast mediaportfolio expansion

Related Companies

$AMRX

Read the original article

Published by GlobeNewswire Clinical Studies on July 17, 2026 12:00 PM

Read Original